Modeling therapy resistance in genetically engineered mouse cancer models

Area of Science:

• Oncology
• Pharmacology
• Translational Medicine

Background:

• Drug resistance is a significant challenge in cancer treatment, impacting both traditional chemotherapy and targeted therapies.
• Current understanding of specific drug resistance mechanisms in patients remains incomplete, hindering effective strategy development.
• Genetically engineered mouse models (GEMMs) that mimic human cancers offer a promising platform for in vivo research.

Purpose of the Study:

• To highlight the utility of GEMMs for investigating in vivo mechanisms of anti-cancer drug resistance.
• To explore the application of GEMMs in analyzing intrinsic and acquired resistance.
• To demonstrate the potential of GEMMs for characterizing residual cancer cells post-treatment.

Main Methods:

• Utilizing genetically engineered mouse models that develop human-like tumors.
• Analyzing intrinsic and acquired drug resistance mechanisms within these models.
• Characterizing residual tumor cells that survive anti-cancer drug treatment.

Main Results:

• GEMMs provide a relevant in vivo system to study complex drug resistance phenomena.
• These models allow for the detailed investigation of how cancer cells become resistant to therapies.
• Residual cells surviving treatment can be identified and studied in a physiologically relevant context.

Conclusions:

• Genetically engineered mouse models are valuable tools for elucidating in vivo cancer drug resistance mechanisms.
• These models facilitate the study of both initial and developing resistance, as well as treatment survivors.
• Optimization of drug regimens and combinations can be effectively performed in GEMMs before clinical application.